Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

C4 Therapeutics (CCCC) Cash & Equivalents (2019 - 2025)

C4 Therapeutics (CCCC) has 7 years of Cash & Equivalents data on record, last reported at $74.6 million in Q4 2025.

  • For Q4 2025, Cash & Equivalents rose 34.42% year-over-year to $74.6 million; the TTM value through Dec 2025 reached $74.6 million, up 34.42%, while the annual FY2025 figure was $74.6 million, 34.42% up from the prior year.
  • Cash & Equivalents reached $74.6 million in Q4 2025 per CCCC's latest filing, up from $58.8 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $281.1 million in Q2 2021 and bottomed at $29.8 million in Q4 2022.
  • Average Cash & Equivalents over 5 years is $81.0 million, with a median of $60.3 million recorded in 2023.
  • Peak YoY movement for Cash & Equivalents: plummeted 79.62% in 2022, then surged 325.46% in 2023.
  • A 5-year view of Cash & Equivalents shows it stood at $76.1 million in 2021, then crashed by 60.91% to $29.8 million in 2022, then soared by 325.46% to $126.6 million in 2023, then crashed by 56.16% to $55.5 million in 2024, then skyrocketed by 34.42% to $74.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cash & Equivalents were $74.6 million in Q4 2025, $58.8 million in Q3 2025, and $78.2 million in Q2 2025.